×

AVROBIO, Inc. Appoints Ian Clark to Its Board of Directors

Appointment of Industry Veteran Ian Clark Brings Wealth of Leadership, Strategic and Operational Experience

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the appointment of Ian Clark to its Board of Directors. Ian Clark, former CEO of Genentech, will join as an independent director effective immediately.

“Ian brings decades of experience leading some of our industry’s most innovative companies to AVROBIO,” said Geoff MacKay, President and CEO of AVROBIO. “His breadth of knowledge and strategic insight will be invaluable to the Company as we continue to focus on rapid expansion of our portfolio of gene therapies to treat rare diseases. We are thrilled to welcome him to the AVROBIO team and we look forward to his contributions.”

“AVROBIO’s gene therapy programs aim to deliver lasting and meaningful benefits for patients with serious, genetic diseases. I am excited to be involved with a team advancing such transformative medicines,” said Mr. Clark.

Mr. Clark is currently serving as an Operating Partner within Clarus Ventures. Mr. Clark served as Chief Executive Officer of Genentech and as Head of Roche's North American Commercial Operations. Mr. Clark joined Genentech in 2003 as Senior Vice President and General Manager, Bio-Oncology. By 2006, he was named Executive Vice President, Commercial Operations and became a member of the Executive Committee. Mr. Clark was named head of Global Product Strategy and Chief Marketing Officer of Roche in April 2009. Prior to joining Genentech, Mr. Clark served as general manager of Novartis Canada, where he oversaw all of the company's operations, and as Chief Operating Officer for Novartis United Kingdom.

Currently, Mr. Clark serves on the boards of Agios Pharmaceuticals, Inc., Corvus Pharmaceuticals, Inc. and Shire plc. Mr. Clark recently was a member of the Kite Pharma board until its acquisition by Gilead Inc. Since 2009, he has served on the boards of directors of the Biotechnology Industry Organization (BIO), the Gladstone Foundation and the Federal Reserve Bank of San Francisco's Economic Advisory Council. Mr. Clark received a Bachelor of Science Degree and an Honorary Doctorate in Biological Sciences from Southampton University in the United Kingdom.

About AVROBIO, Inc.
AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical-stage company developing disruptive therapies that have the potential to transform patients’ lives with a single dose. The Company is focused on the development of its Phase 1 program in Fabry disease and pre-IND programs in Cystinosis and Gaucher disease, while actively building a pipeline of therapies to treat Pompe disease and other rare and non-rare genetic diseases. AVROBIO also has an immuno-oncology gene therapy program. AVROBIO is headquartered in Cambridge, MA and has offices in Toronto, ON. For additional information, visit www.avrobio.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171109005113/en/

AVROBIO, Inc.
Kirsten Dupuis, +1-617-914-8403
kirsten.dupuis@avrobio.com

Source: AVROBIO, Inc.